Applied Medical Resources v. Covidien
This article was originally published in The Gray Sheet
Executive Summary
Central California federal court jury rules in favor of Covidien's U.S. Surgical subsidiary, finding that it does not infringe an Applied Medical Resources patent related to trocar seal technology, Covidien says Feb. 20. Filed in 2003, AMR's complaint centered on U.S. Surgical's Versaseal Plus system, which maintains a seal during surgery when instruments are inserted or withdrawn. Morgan Stanley analyst Glenn Reicin estimates that Covidien could have faced damages and associated legal costs totaling about $400 million